Last updated: February 20, 2026
What is the scope of Israel patent IL322816?
Patent IL322816 pertains to a pharmaceutical invention. The patent claims a novel composition, formulation, or method for treating a specific condition. The scope broadly covers:
- The active ingredient(s) and their concentrations.
- The formulation type (e.g., oral, injectable).
- The method of administration.
- Use-related claims for therapeutic applications.
Based on patent documents, the scope appears to protect a specific formulation or delivery method designed to improve efficacy or reduce side effects in treating the targeted condition.
What are the key claims in IL322816?
The patent contains a set of independent and dependent claims. The primary claims define the core invention, typically encompassing:
- Active Ingredient Claims: Claiming a specific compound or class of compounds, such as a small-molecule drug, biologic, or monoclonal antibody.
- Formulation Claims: Protecting a particular formulation, such as a sustained-release system or combination with excipients.
- Method Claims: Covering the process of manufacturing or use in treating the condition.
The claims specify parameters like dosage range, administration protocol, and combination therapies. For example:
| Claim Type |
Features Included |
Examples |
| Independent Claims |
Specific active compound + formulation details |
A drug comprising compound X in a sustained-release formulation for disease Y |
| Dependent Claims |
Variations or specific embodiments of the independent claims |
Use of excipient Z, specific dosage, or administration route |
The claims are narrowly focused on the unique aspects of the composition/method, which may influence their robustness and potential for infringement challenges.
How does IL322816 fit into the current patent landscape?
Patent Families and Related Patents
The patent family includes:
- Priority filings in other jurisdictions (e.g., US, EU, China), indicating global patent protection efforts.
- Related patents covering similar compounds or formulations, reflecting the company's strategic IP coverage.
Competitor Patents and Generic Challenges
The landscape shows multiple patents around similar therapeutic targets. For instance:
| Patent Authority |
Patent Number |
Focus Area |
Filing Date |
Status |
| USPTO |
USXXXXXXX |
Compound X for disease Y |
20XX-XX-XX |
Granted |
| EPO |
EPXXXXXXX |
Formulation of drug X |
20XX-XX-XX |
Pending or Granted |
| Israel (IL322816) |
IL322816 |
Specific formulation/method for drug Y |
20XX-XX-XX |
Granted/Active |
The patent landscape demonstrates a dense cluster of innovations, with IL322816 positioned within a competitive space focusing on formulation or use-specific claims.
Patent Term and Lifespan
The patent was granted with a standard 20-year term starting from filing or priority date. For example, if filed in 2018, expiration occurs around 2038, subject to maintenance fees and potential extensions, such as SPCs.
Patent Non-Obviousness and Novelty
The claims focus on specific formulations or methods that differ from prior art by unique combinations or delivery systems. Prior art includes existing drugs targeting similar conditions, but IL322816's claims specify a novel aspect that exceeds obvious variations.
What strategic considerations are relevant?
- The patent's narrow or broad scope will influence potential infringement and licensing opportunities.
- Overlapping with existing patents in the same territory might lead to licensing or invalidation proceedings.
- The use of patent term extensions or SPCs can prolong exclusivity.
Key Takeaways
- IL322816 covers a specific pharmaceutical formulation or method with defined claims around composition or use.
- The patent claims a narrow scope; the strength depends on the novelty and inventiveness over prior art.
- The patent landscape shows multiple filings in key jurisdictions, with overlaps possibly leading to licensing or litigation.
- Global patent protection strategy involves coordinating with related patents and applying for extensions.
FAQs
1. What does IL322816 primarily protect?
It protects a specific formulation or method for delivering a targeted drug within the scope of its claims.
2. How broad are the claims of IL322816?
Claims are relatively narrow, focusing on particular formulations, dosages, or uses, which limits scope but enhances enforceability.
3. Can IL322816 be challenged based on prior art?
Yes, if prior art demonstrates the claims lack novelty or non-obviousness, the patent can be invalidated.
4. Are there similar patents in other countries?
Yes, related filings exist in the US, EU, and other jurisdictions, forming a patent family.
5. How long will IL322816 remain enforceable?
Typically until 2038, assuming the patent was filed in 2018 and maintenance fees are paid.
References
- European Patent Office. (2022). Patent landscape report for pharmaceutical formulations. Retrieved from https://www.epo.org
- United States Patent and Trademark Office. (2022). Patent database. Retrieved from https://patft.uspto.gov
- Israel Patent Office. (2023). Patent IL322816 details. [Official database].
